These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

572 related items for PubMed ID: 27453079

  • 41. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.
    Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V.
    Eur Child Adolesc Psychiatry; 2017 Aug; 26(8):875-897. PubMed ID: 28258319
    [Abstract] [Full Text] [Related]

  • 42. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
    Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS.
    J Clin Psychiatry; 2008 Dec; 69(12):1938-47. PubMed ID: 19192455
    [Abstract] [Full Text] [Related]

  • 43. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
    Weiss MD, Cutler AJ, Kollins SH, Donnelly GAE.
    J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
    [Abstract] [Full Text] [Related]

  • 44. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy.
    Hirota T, Schwartz S, Correll CU.
    J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):153-73. PubMed ID: 24472251
    [Abstract] [Full Text] [Related]

  • 45. Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy.
    Ota T, Yamamuro K, Okazaki K, Kishimoto T.
    Drug Des Devel Ther; 2021 Feb; 15():1965-1969. PubMed ID: 34007156
    [Abstract] [Full Text] [Related]

  • 46. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L.
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [Abstract] [Full Text] [Related]

  • 47. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
    Simonoff E, Taylor E, Baird G, Bernard S, Chadwick O, Liang H, Whitwell S, Riemer K, Sharma K, Sharma SP, Wood N, Kelly J, Golaszewski A, Kennedy J, Rodney L, West N, Walwyn R, Jichi F.
    J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
    [Abstract] [Full Text] [Related]

  • 48. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L.
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [Abstract] [Full Text] [Related]

  • 49. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
    Lachaine J, Sikirica V, Mathurin K.
    BMC Psychiatry; 2016 Jan 16; 16():11. PubMed ID: 26774811
    [Abstract] [Full Text] [Related]

  • 50. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.
    Biederman J, Quinn D, Weiss M, Markabi S, Weidenman M, Edson K, Karlsson G, Pohlmann H, Wigal S.
    Paediatr Drugs; 2003 Jan 16; 5(12):833-41. PubMed ID: 14658924
    [Abstract] [Full Text] [Related]

  • 51. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial.
    Mohammadi MR, Kashani L, Akhondzadeh S, Izadian ES, Ohadinia S.
    J Clin Pharm Ther; 2004 Apr 16; 29(2):139-44. PubMed ID: 15068402
    [Abstract] [Full Text] [Related]

  • 52. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, McBurnett K, White C, Youcha S.
    J Child Adolesc Psychopharmacol; 2014 Jun 16; 24(5):245-52. PubMed ID: 24945085
    [Abstract] [Full Text] [Related]

  • 53. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR, Hafezi P, Galeiha A, Hajiaghaee R, Akhondzadeh S.
    Acta Med Iran; 2012 Jun 16; 50(11):723-8. PubMed ID: 23292622
    [Abstract] [Full Text] [Related]

  • 54. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY, Pan YL, Lin HY, Huang LW, Gau SS.
    J Child Adolesc Psychopharmacol; 2015 Sep 16; 25(7):566-73. PubMed ID: 26222447
    [Abstract] [Full Text] [Related]

  • 55. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR, Wilens TE, Bostrom S, Arnold VK, Marraffino A, Cutler AJ, López FA, DeSousa NJ, Sallee FR, Incledon B, Newcorn JH.
    J Child Adolesc Psychopharmacol; 2017 Aug 16; 27(6):474-482. PubMed ID: 29172680
    [Abstract] [Full Text] [Related]

  • 56. Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial.
    Dehbozorghi S, Bagheri S, Moradi K, Shokraee K, Mohammadi MR, Akhondzadeh S.
    Psychiatry Clin Neurosci; 2019 Nov 16; 73(11):690-696. PubMed ID: 31294924
    [Abstract] [Full Text] [Related]

  • 57. ▼Guanfacine for ADHD in children and adolescents.
    Drug Ther Bull; 2016 May 16; 54(5):56-60. PubMed ID: 27173784
    [Abstract] [Full Text] [Related]

  • 58. Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study.
    Baziar S, Aqamolaei A, Khadem E, Mortazavi SH, Naderi S, Sahebolzamani E, Mortezaei A, Jalilevand S, Mohammadi MR, Shahmirzadi M, Akhondzadeh S.
    J Child Adolesc Psychopharmacol; 2019 Apr 16; 29(3):205-212. PubMed ID: 30741567
    [Abstract] [Full Text] [Related]

  • 59. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
    Wigal SB, Childress A, Berry SA, Belden H, Walters F, Chappell P, Sherman N, Orazem J, Palumbo D.
    J Child Adolesc Psychopharmacol; 2017 Oct 16; 27(8):690-699. PubMed ID: 28557548
    [Abstract] [Full Text] [Related]

  • 60. An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder.
    Zheng Y, Liang JM, Gao HY, Yang ZW, Jia FJ, Liang YZ, Fang F, Li R, Xie SN, Zhuo JM.
    Chin Med J (Engl); 2015 Nov 20; 128(22):2988-97. PubMed ID: 26608976
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.